JAK/TYK2 Inhibition: New Frontiers in the Treatment of Psoriasis
JAK/TYK2 Inhibition: New Frontiers in the Treatment of Psoriasis
Release Date: December 16, 2020
Last Reviewed: December 15, 2020
Expiration Date: December 16, 2021
Time to Complete Activity: 1 hour
April W. Armstrong, MD, MPH
Associate Dean, Clinical Research
Professor of Dermatology
Director, Clinical Research Support, Southern California CTSI
Keck School of Medicine
University of Southern California
Los Angeles, CA
Seemal R. Desai, MD, FAAD
Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
Gary Goldenberg, MD
Assistant Clinical Professor, Dermatology
Mount Sinai School of Medicine
New York, NY
This activity is provided by the University of Cincinnati.
Paradigm Medical Communications, LLC is the educational partner.
Disclosure of Commercial Support
This activity is supported by an educational grant from Bristol-Myers Squibb.
This activity has been designed to address the educational needs of dermatology clinicians. It may also be of benefit to rheumatology and primary care clinicians, as well as other healthcare providers involved with or interested in the management of patients with psoriasis.
Statement of Need
Psoriasis is a common autoimmune disorder with associated comorbidities that are more than skin deep. Patients with psoriasis are at increased risk for cardiovascular and metabolic disease, malignancies, and anxiety/depression. This activity will provide clinicians with a solid foundation for understanding the pathophysiology of psoriasis along with other autoimmune diseases, how this pathophysiology informs treatment options, and the most recent clinical trial data for current and emerging agents and management recommendations available to guide therapy selection.
Upon proper completion of this activity, participants should be better able to:
- Identify the JAK/TYK2-STAT–mediated pathways involved in the pathophysiology of psoriasis
- Summarize evidence for the efficacy, safety, and mechanisms of action for new and emerging agents in psoriasis, and the implications for treatment
- Apply current research findings and recommendations to the treatment of psoriasis and comorbidities
- Pathophysiology of Psoriasis
- JAK/TYK2 Inhibitors in Psoriasis Data
- Psoriasis Treatment Guidelines
- New Directions in Psoriasis Therapy: The Role of Emerging JAK/TYK2 Inhibitors in Psoriasis
Physician Accreditation Statement
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Canadian Continuing Professional Development (CPD) Credit: Through an agreement between the ACCME and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Instructions for Participation
To receive a CME certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
There is no fee required for participation in this activity.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or email@example.com.
This certified CME activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.
For desktops (Windows/Mac)
Microsoft Edge 40 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Technical Support: If you have any technical problems or playback issues email us at firstname.lastname@example.org.
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
April W. Armstrong, MD MPH
Consulting Fees: AbbVie Inc.; Bristol-Meyers Squibb Company; Dermavant Sciences, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; LEO Pharma Inc.; Modernizing Medicine; Novartis; Ortho Dermatologics; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi Genzyme; Sun Pharmaceutical Industries Ltd
Grant/Research Support: AbbVie Inc.; Bristol-Meyers Squibb Company; Dermavant Sciences, Inc.; Dermira, Inc.;
Eli Lilly and Company; Janssen Pharmaceuticals, Inc; Kyowa Kirin Pharmaceutical Research, Inc.; LEO Pharma Inc.; Novartis; Regeneron Pharmaceuticals Inc; Sanofi Genzyme; UCB, Inc.
Seemal R. Desai, MD, FAAD
Consulting Fees: Bristol-Myers Squibb Company; Pfizer Inc
Speakers Bureau: Pfizer Inc
Gary Goldenberg, MD
Consulting Fees: AbbVie Inc.; Eli Lilly and Company; Pfizer Inc
Speakers Bureau: AbbVie Inc.; Eli Lilly and Company; Pfizer Inc
University of Cincinnati staff members and reviewers have no financial relationships to disclose.
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Resolution of Conflict of Interest
The University of Cincinnati has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
If you have any questions or comments, please email us at email@example.com.
© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.